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ABSTRACT
The gold standard for the laboratory diagnosis of COVID-19 is the reverse transcription 
quantitative real-time polymerase chain reaction (RT-qPCR) assay, which searches for 
SARS-CoV-2 target genes in nasopharyngeal/oropharyngeal (NP/OP) samples, and its 
performance depends on the quantity and quality of the RNA input. This study compared 
the performance and cost-effectiveness of three different kits/reagents for RNA extraction 
used in COVID-19 diagnosis in Sao Paulo, Brazil. A total of 300 NP/OP samples belonging 
to suspected cases of COVID-19 stored in a biorepository were randomly selected, and 
RNA was extracted using (i) automated extraction (Loccus, Extracta Kit FAST), (ii) manual 
extraction (BioGene Kit, Bioclin, Quibasa), and (iii) quick extraction methods (Lucigen, 
Quick DNA Extract Kit). Next, the samples were tested using RT-qPCR for SARS-CoV-2 
with the Allplex 2019-nCoV modified assay and the Charité-Berlin protocol. All assays/kits 
were used according to the manufacturer’s instructions. For the Allplex kit, the sensitivity in 
detecting SARS-CoV-2 with previously extracted RNA by different procedures was 100.0% 
for Loccus, 100.0% for BioGene and 91.9% for Quick. Using the Charité-Berlin protocol, 
the sensitivities were 81.4% for Loccus, 81.2% for BioGene and 60.7% for Quick. The 
least sensitive target gene and the gene most affected by RNA extraction procedures was 
the RNA-dependent RNA polymerase gene (Charité-Berlin protocol). No false-positive 
SARS-CoV-2 results were detected using RNA obtained from any of the different protocols. 
In conclusion, Loccus and BioGene RNA extractions were efficient for RT-qPCR assays, 
and although the BioGene procedure is less expensive, Loccus is the best choice because it 
allows the rapid handling of hundreds or thousands of samples, a desirable feature during 
pandemics. Although less sensitive, the Quick extraction is useful during outbreaks coupled 
with the Allplex amplification kit for SARS-CoV-2 diagnosis (κ = 0.925). 
KEYWORDS: COVID-19. SARS-CoV-2. SARS-CoV-2 RT-PCR. SARS-CoV-2 molecular 
diagnosis. RNA extraction methods. Assays performances. Cost-effectiveness. RT-qPCR.
INTRODUCTION
Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) 
for SARS-CoV-2, the new coronavirus that causes severe acute respiratory syndrome, 
is the gold standard for the laboratory diagnosis of COVID-19. It is preferably 
performed soon after the onset of using nasopharyngeal/oropharyngeal (NP/OP) 
secretions obtained with the help of swabs. RT-qPCR for SARS-CoV-2 is carried out 
using primer-probe sets targeting the highly conserved sequences of the envelope (E), 
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nucleocapsid (N), and RNA-dependent RNA polymerase 
(RdRP) viral genes1-4. RT-qPCR performance for SARS-
CoV-2 depends on the quality of the specimen, the date of 
collection, the presence of PCR inhibitors, the handling and 
quick delivery of specimens, and the quantity and quality 
of extracted RNA1-4. 
Since the beginning of the SARS-CoV-2 pandemic, 
several approaches/kits and molecular diagnostic reagents 
have been described in the literature and are available in 
the market1-4; however, because of the speed at which the 
virus has spread worldwide and the scarcity of kits and 
supplies, various government entities, such as the Brazilian 
Ministry of Health, have granted authorization for the use 
of these kits and protocols without a previous and accurate 
evaluation of their performance. 
Brazil is ranked third in the number of COVID-19 cases 
worldwide5, and on March 25, 2021, 14,340,787 confirmed 
cases and 390,797 deaths were reported to the Ministry of 
Health through the Health Surveillance Secretariat6. Sao 
Paulo State, located in Southeast Brazil, has the highest 
number of confirmed COVID-19 cases: 2,834,738 cases 
and 61,463 deaths6, and the city of Sao Paulo (the largest 
in Latin America) accounts for 991,683 cases and 26,532 
deaths7. Thus, this State and its capital city has received a 
large number of samples for analysis, from suspected cases 
of COVID-19 in a daily basis. 
The Institute Adolfo Lutz (IAL) is a public health 
laboratory located in Sao Paulo city and is the reference 
laboratory for respiratory viruses, receiving many samples 
daily for diagnosis and surveillance. In a previous study, 
we compared the performance and cost-effectiveness of 
seven assays/kits available for COVID-19 routine molecular 
diagnosis, and found that, although there were some 
sensitivity and specificity differences among the assays, all 
assays/kits showed good performances (all of the Cohen’s 
Kappa index were above 0.893). We confirmed that the 
assays/kits employing multiplex RT-qPCR methods had 
the best cost-benefit parameters8. In the present study, we 
decided to compare the diagnostic performance and cost-
effectiveness of three different RNA extraction methods 
because this is another bottleneck in COVID-19 diagnosis 
due to the shortage of reagents and supplies, the fact that 
the procedure is time-consuming, and thousands of samples 
must be daily processed. 
MATERIALS AND METHODS
Clinical specimens
In the present study, 300 NP/OP samples collected 
between September and October 2020 and sent to IAL for 
COVID-19 molecular diagnosis. They were used for the 
comparative analysis of three different RNA extraction 
methods for SARS-CoV-2 RNA target gene detection. The 
samples were collected, placed in saline transport solution 
and stored at -70 °C in a biorepository. The only criterion 
for selecting these samples was a minimum volume of 
800  µL. The samples were divided into three aliquots: 
200 µL for automated RNA extraction, 400 µL for manual 
RNA extraction, and 150 µL for quick RNA extraction. 
The assays were conducted blindly, and the authors did not 
know the SARS-CoV-2 result of the samples at the time 
of diagnosis and the cycle threshold (Ct) values of these 
samples were also unknown.
Methods
For the automated RNA extraction, the Loccus kit/
equipment, the Extracta Fast kit (Cod. MVXA-P016 Fast) 
and the Loccus Extracta 32 equipment (Sao Paulo, Brazil) 
were employed. Briefly, the Loccus extraction procedure 
involves four steps: sample lysis, nucleic acid binding 
to electromagnetic beads covered with silicon dioxide, 
washing and elution. All steps were conducted according 
to the manufacturer’s instructions in 32 deep well plates 
for approximately 1 h. 
For the manual RNA extraction, the BioGene DNA/
RNA viral kit (Bioclin Quibasa, MG, Brazil) was 
used, and the extraction was conducted according to 
the manufacturer’s instructions. Briefly, the BioGene 
extraction has the same steps as the Loccus extraction 
(lysis, binding, washing and elution), however, it 
differs in the type of handling and the time expended 
in the procedure. It was conducted in a biosafety cabin, 
employed tubes, one of which contained a column of 
silica for nucleic acids binding, and required a vortex, a 
dry thermoblock and a centrifuge equipment. The number 
of handling steps and hazards reduced the number of 
extractions; for 32 samples, the time required was 2.5 h.
To ascertain the quantity of RNA was sufficient for 
RT-qPCR analyses in all extraction procedures (automated 
and manual), two extractions were performed and the RNA 
pool obtained was maintained at -70 °C and used up to one 
day after the extraction. 
For the quick RNA extraction, the Lucigen 
QuickExtract™ DNA Extraction Solution (Lucigen 
Corporation, Middleton, WI, USA) was employed. Briefly, 
for each Quick extraction, 150 µL of sample was mixed 
by vortexing in 150 µL of Lucigen buffer, subjected to a 
heat shock at 95 °C for 5 min, cooled in a freezer or in 
ice bath for 5 min, and tested for RT-qPCR SARS-CoV-2 
immediately, or maintained at -70 °C and used up to one 
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day after the extraction. This procedure saves time and 
sample handling, taking approximately 30 min to extract 
32 samples.
For SARS-CoV-2 RNA detection, two RT-qPCR assays 
were employed: Allplex 2019-nCoV modified assay, 
Seegene, Korea8 (provided by the Coordenacao Geral 
de Laboratorios de Saude Publica, CGLAB, Ministry of 
Health and used as a routine procedure at IAL and other 
public health laboratories in Brazil), and the Charité-Berlin 
protocol (employed in public health laboratories in Brazil 
at the beginning of the pandemic) using a P2 probe9. These 
RT-qPCR assays diverge in their composition, target genes, 
labeled probes, methods, interpretation of results and both 
were conducted according to the respective manufacturer’s 
instructions, using 8 µL and 5 µL of RNA input for each 
assay, respectively.
All RT-qPCR reactions were performed in duplicate 
using the QuantStudio 5 Real-Time PCR System (Applied 
Biosystems, CA, USA).
Briefly, the Allplex kit employs as target genes 
and labeled probes E (FAM), N (Cal Red 610), RdRP 
(Quasar  670), and an internal control (IC; HEX) in one 
multiplex RT-qPCR, whereas the Charité-Berlin protocol 
employs the E- and RdRP target genes and probes labeled 
with FAM in two single RT-qPCR assays9. 
We employed primers/probes of the human RnaseP 
gene, as previously described10, as the IC for both 
kit/assay. We did not use the IC of the Allplex kit because it 
did not work well in our laboratory (Ct values more than 35 
and 20% of false-negative results), probably because this IC 
has been standardized for the conditions and the equipment 
Nimbus/STARlet of the Seegene manufacturer (NIMBUS/
STARlet equipment, Franklin, MA, USA), which are not 
available in our laboratory. The Seegene manufacturer 
recently described four kits/equipment for RNA extraction 
that can be used with the Allplex kit: two automatized 
(SEEPREP 32, from Seegene Inc. Korea, and NucliSENS 
easyMAG from BioMérieux SA, Marcy l’Etoile France), 
and two manual RNA extraction kits (Ribospin vRD kit 
from GeneAll Biotechnology Co., Ltd, Seoul, Korea, and 
QIAmp DSP Virus Spin Kit, Qiagen Inc., Hilden, Germany). 
None of these are available in our laboratory.
The Ct limit (cut-off) of 40 was adopted for both kits/
assays. In samples with Ct values close to the cut-off value 
(one Ct under the cut-off), the reactions were repeated in 
duplicate and the characteristics of the exponential/linear 
curves were observed.
The criteria established by the manufacturer for 
considering SARS-CoV-2 positive samples using the Allplex 
kit is the positivity of at least one of the RNA SARS-CoV-2 
gene targets, except when only the E gene is detected, 
when the sample is considered “presumptive positive.” The 
Charité-Berlin protocol considers SARS-CoV-2 positive 
samples when both E and RdRP are detected.
Statistical analysis
The GraphPad Prism software, version 5.03 (GraphPad, 
San Diego, CA, USA) was used for comparisons of Ct 
values among three or more assays using the Kruskal–
Wallis analysis of variance, complemented with the Dunn’s 
multiple comparison test, and the Mann-Whitney U-test 
for the comparison of two assays. Results with a p-value 
of ≤ 0.05 were considered statistically significant. Analysis 
of repeatability and reproducibility were performed by 
calculating the mean Ct value, the standard deviation (SD), 
and the coefficient of variation in percentage (CV). The Ct 
total values considered the mean, SD and CV obtained in 
each reaction. 
The Epi Info, version 3.5.4 software (Atlanta, GA, 
USA) was employed for the comparative analysis of 
the sample final result by each RNA extraction protocol 
and assay/kit, and determined the sensitivity, specificity, 
and Cohen’s Kappa values, which were interpreted as 
follows: perfect (κ = 1.0), almost perfect (1.0 < κ > 0.80), 
substantial (0.80 ≤ κ > 0.60), moderate (0.60 ≤ κ > 0.40), 
fair (0.40 ≤ κ > 0.20), slight (0.20 ≤ κ > 0), or poor (κ = 0). 
Differences in sensitivity of the assays were statistically 
evaluated using the Chi-square test or Fisher’s exact test, 
as appropriate. Statistical significance was set at p ≤ 0.05. 
For the cost-effectiveness evaluation of the three RNA 
extraction protocols both, cost and consequences were 
considered (cost in American dollars of each assay/kit 
acquired in May 2020, number of samples analyzed in each 
protocol, time consumption, ease of performing, and the 
assay sensitivity and specificity)11.
Ethical approval
All procedures were performed according to the 
principles established in the Declaration of Helsinki of 
1975, as revised in 1975, 1983, 1989, 1996, and 2000. 
The study was approved by the IAL Ethics Committee for 
Research CTC Nº 21M-2020 under the protocol Nº CAAE 
– 33282820.8.0000.0059. 
RESULTS
Table 1 presents the final SARS-CoV-2 results in 
300 NP/OP samples using three different RNA extraction 
procedures and tested with two different molecular kits/
protocols. These results considered the manufacturer’s 
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criteria, and showed that, despite the same efficiency of 
Loccus and Biogene RNA extraction procedures, more 
SARS-CoV-2 positive samples were found using the Allplex 
kit compared to the Charité-Berlin protocol: 272/300 
(90.7%) vs. 210/300 (70.0%), respectively. The ability to 
detect SARS-CoV-2 positive samples was lower with the 
Quick RNA extraction procedure, particularly when the 
Charité-Berlin protocol was employed: 96/300 (32.0%) 
(Table 1). 
When analyzing the Ct values of the positive samples for 
the RNA extraction procedure and diagnostic kit/protocol, 
low median Ct values (higher SARS-CoV-2 viral load) 
were detected using the Loccus RNA extraction procedure, 
irrespective of the target gene analyzed and kit/protocol 
employed for diagnosis: E, N, and RdRP in the Allplex kit 
(Figure 1), and E and RdRP in the Charité-Berlin protocol 
(Figure 2). In contrast, high Ct values were detected when 
using the Quick RNA extraction procedure, except for 
the RdRP target gene using the Charité-Berlin protocol, 
which resulted in Ct values similar to those detected by the 
BioGene extraction procedure (Figure 2). Overall, almost 
all comparative analyses of Ct values revealed statistically 
significant differences (p ≤ 0.001) (Figures 1 and 2). 
Statistically significant differences were detected when 
the Ct values of E- and RdRP target genes were analyzed 
using the Allplex kit and the Charité-Berlin protocol. For the 
E gene, irrespective of the RNA extraction procedure, low 
Ct values were detected using the Allplex kit (Figure 3A). 
In contrast, when the Ct values for the RdRP gene were 
analyzed, low Ct values were detected using the Charité-
Berlin protocol, showing significant differences in samples 
in which RNA was extracted using the BioGene and the 
Quick procedures (Figure 3B).
Details concerning the results shown in Figures 1, 2, and 
3 are presented in Table 2. Overall, the median Ct values 
varied from 23 to 29, and the mean Ct values ranged from 
23.33 to 29.13. A lower CV was detected for the RdRP 
target gene; nonetheless, this target gene showed fewer 
positive results in both kits/protocols. In general, the major 
Ct values were detected using the Quick RNA extraction 
procedure (Table 2). 
Concerning the number of target genes detected in 
SARS-CoV-2 positive samples using the Allplex kit 
(n  =  272), no sample fell in the “presumptive positive” 
condition (positivity only for the E gene) irrespective of the 
RNA extraction procedure. The majority of samples were 
positive for the three target genes (E, RdRP and N), and only 
Table 1 - Results of SARS-CoV-2 molecular diagnosis using samples from Sao Paulo, Brazil and different RNA extraction procedures.
RNA extraction 
procedure





272 28 300 90.7
BioGene 272 28 300 90.7
Quick 248 52 300 82.7
Loccus
Charité (Berlin)
210 90 300 70.0
BioGene 209 91 300 69.7
Quick 96 204 300 32.0
Criteria for positivity as described in Materials and Methods
Figure 1 - Cycle threshold (Ct) values obtained for samples that 
were positive to different SARS-CoV-2 target genes using the 
Loccus, BioGene, and Quick RNA extraction procedures, and 
the Allplex 2019-nCoV assay. Differences statistically significant 
are depicted as *p < 0.05, **p ≤ 0.001, and ***p ≤ 0.0001 using 
the Kruskal–Wallis test complemented with Dunn’s multiple 
comparison test.
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12 samples were positive for two targets [four (E and N) and 
eight (RdRP and N)], and 13 for only one target (N) when 
using RNA obtained with the Loccus extraction procedure. 
Using the BioGene RNA extraction, the majority of samples 
were positive for three targets, eight for two targets [six (E 
and N) and two (RdRP and N)], and 14 samples for only 
one target (N). By the Quick extraction, although there were 
fewer positive cases (n = 248), the majority of samples 
were positive for three target genes, two samples for two 
targets [one (E and N) and one sample for (RdRP and N)], 
and 44 samples for only one target (N).
When the results were analyzed using the Charité-Berlin 
protocol, 275, 277, and 229 samples were positive for the 
E gene when using RNA extracted by Loccus, BioGene, 
and Quick procedures, respectively, whereas only 210, 209, 
and 96 samples were confirmed SARS-CoV-2 positive for 
the RdRP gene (Table 2), showing a lower sensitivity of the 
RdRP target gene and a possible interference of residues 
present in the extracted RNA using the Quick protocol. 
All samples considered truly positives (n = 272) or 
negatives (n = 28) for SARS-CoV-2 amplified the IC 
(RNaseP in this study), and low Ct values were detected in 
SARS-CoV-2 negative samples with statistically significant 
differences compared to SARS-CoV-2 positive samples 
(Figure 4). Table 3 shows the Ct values obtained by the IC 
RNase gene protocol in detail, confirming the presence of 
RNA in such samples.
We sequenced SARS-CoV-2 of several samples that 
presented with discordant results in the diagnostic assays 
and RNA extraction procedures, as follows: Allplex 
positive and Quick RNA extraction negative (n = 4), 
Allplex and Charité positive and Loccus positive but 
BioGene extraction negative (n = 1), and Allplex positive 
and Charité negative irrespective of the RNA extraction 
procedure (n = 29). Sequencing was performed using 
cDNA samples obtained by the SuperScript IV Reverse 
Transcriptase (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA) according to the manufacturer’s 
recommendations, and the whole genome sequencing 
was carried out using an Ion Torrent S5 platform 
and the AmpliSeq™ SARS-CoV-2 (Thermo Fisher 
Figure 2 - Cycle threshold (Ct) values obtained for samples that 
were positive to different SARS-CoV-2 target genes using the 
Loccus, BioGene, and Quick RNA extraction procedures, and 
the Charité-Berlin protocol. Differences statistically significant 
are depicted as *p < 0.05, **p ≤ 0.001, and ***p ≤ 0.0001 using 
the Kruskal–Wallis test complemented with Dunn’s multiple 
comparison test.
Figure 3 - Cycle threshold (Ct) values obtained for samples 
that were positive to E- and RdRP target genes using the 
Loccus, BioGene, and Quick RNA extraction procedures, tested 
by the Allplex 2019-nCoV assay and Charité-Berlin protocol. 
Differences statistically significant were depicted and detected 
using the Mann-Whitney U-test.
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Scientific, Waltham, MA, USA), which allows a complete 
sequencing of SARS-CoV-2 lineages without gaps. 
Thereafter, these sequences were sent to the Global 
Initiative on Sharing Avian Influenza Data, Accession 
Numbers: EPI_ISL_693215 to EPI_ISL_693243 (Allplex 
positive and Charité negative), EPI_ISL_693244 to 
EPI_ISL_693247 (Allplex positive and Quick RNA 
negative), and EPI_ISL_693248 (Allplex and Charité 
positive and Loccus positive, but BioGene negative).
In summary, considering the results of the Allplex kit 
as true as it has detected more SARS-CoV-2 target genes 
and showed the best performance in a previous comparative 
study of seven kits/assays employed in Sao Paulo, Brazil 
for COVID-19 diagnosis8, and was able to detect SARS-
CoV-2 by sequencing from several samples that presented 
discordant results in the diagnostic assays and RNA 
extraction procedures, we calculated the sensitivity and 
specificity of the assays for each RNA extraction procedure, 
and the Cohen’s Kappa index (κ) of the assays. Using the 
Allplex kit, the sensitivity in detecting SARS-CoV-2 using 
the RNA extracted by different procedures was 100.0% for 
Loccus, 100.0% for BioGene, and 91.9% for Quick. Using 
the Charité-Berlin protocol, the sensitivity dropped to 81.4% 
for Loccus, 81.2% for BioGene, and 60.7% for Quick (all 
p < 0.000). The lowest sensitivity of target gene detection 
that was most affected by RNA extraction procedures was 
the RdRP gene of the Charité-Berlin protocol. No false-
positive SARS-CoV-2 results were detected using the three 
RNA procedures (specificity of 100.0%). Using the Allplex 
kit, a perfect agreement of results (κ = 1.0) was detected 
Table 2 - Analysis of the cycle threshold (Ct) values obtained for each SARS-CoV-2 target gene using three RNA extraction 
procedures and two RT-qPCR assays.
Assay Allplex 2019-nCoV - Seegene (N=272 +) Charité-Berlin protocol (N=210 +)
Gene E N RdRP E RdRP
RNA extraction 
procedure
Loccus BioGene Quick Loccus BioGene Quick Loccus BioGene Quick Loccus BioGene Quick Loccus BioGene Quick
N+ 251 255 198 266 270 248 255 250 195 275 277 229 210 209 96
Minimum 13 14 16 13 15 16 14 16 18 15 14 17 15 16 19
25% percentile 19 22 24 20 22 24 21 24 26 22 23 25 21 23 24
median 23 25 27 24 27 27 24 27 29 25 27 28 24 26 26
75% percentile 27 29 31 28 30 31 28 31 32 29 31 33 27 30 28
maximum 37 38 37 37 38 39 39 39 38 38 38 38 35 38 33
Mean 23.33 25.45 27.17 24.48 26.48 27.38 24.8 27.51 29.13 25.64 26.8 28.61 24.19 26.52 25.95
Std. deviation 4.955 4.906 4.1 4.97 5,045 4.835 5.224 4.828 4.218 4.96 5.167 4.725 3.906 4.308 3.048
Std. Error 0.313 0.3072 0.2914 0.3047 0.307 0.307 0.3272 0.3054 0.3021 0.2991 0.3105 0.3122 0.2695 0.298 0.3111
Lower 95% CI of 
mean
22.71 24.85 26.6 23.89 25.87 26.78 24.16 26.91 28.53 25.05 26.19 27.99 23.66 25.93 25.33
Upper 95% CI of 
mean
23.94 26,.06 27.75 25.08 27.08 27.99 25.44 28.11 29.72 26.23 27.41 29.22 24.72 27.11 26.57
Coefficient of 
variation
21.24% 19.27% 15.09% 20.30% 19.05% 17.66% 21.07% 17.55% 14.48% 19.35% 19.28% 16.52% 16.15% 16.24% 11.75%
Geometric mean 22.8 24.97 26.85 23.98 25.99 26.95 24.26 27.08 28.82 25.15 26.28 28.21 23.87 26.17 25.77
Lower 95% CI of 
geo. mean
22.2 24.37 26.27 23.39 25.39 26.35 23.65 26.48 28.23 24.57 25.67 27.59 23.35 25.59 25.15
Upper 95% CI of 
geo. mean
23.42 25.59 27.44 24.58 26.6 27.56 24.9 27.69 29.42 25.75 26.91 28.83 24.41 26.76 26.4
N+ = number of RT-qPCR positive samples; E = envelope gene; N = nucleocapsid; RdRP = RNA-dependent RNA polymerase; Std. = standard; CI = confidence 
interval; geo. = geometric
Figure 4 - Cycle threshold (Ct) values obtained for samples 
that were positive and negative to SARS-CoV-2 using the 
Loccus, BioGene, and Quick RNA extraction procedures, and 
the IC corresponding to the RNase target gene amplification. 
Differences statistically significant are depicted as ***p ≤ 0.0001 
using the Kruskal–Wallis test complemented with Dunn’s 
multiple comparison test.
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using Loccus and BioGene RNA extractions, and an almost 
perfect agreement (κ = 0.925) using Quick extraction. When 
the Charité-Berlin protocol was employed, substantial 
agreement of results was detected using different RNA 
extraction protocols: Loccus κ = 0.825, BioGene κ = 0.823 
and Quick κ = 0.621. 
The cost-effectiveness of the three RNA extraction 
procedures was calculated, and the results are presented 
in Table 4. Considering the costs of reagents and supplies, 
ease of performance, time consumption, results obtained 
(sensitivity of SARS-CoV-2 detection), and the number of 
tests released during outbreaks, the Loccus protocol was 
the best choice.
DISCUSSION
In view of the COVID-19 pandemic in Brazil, especially 
in Sao Paulo5-7, continuous studies searching for ways to 
save time and costs in SARS-CoV-2 diagnosis are required. 
Therefore, we have studied the performance and cost-
effectiveness of assays/kits employed in SARS-CoV-2 
RNA gene detections in samples from suspected cases of 
COVID-19 in Sao Paulo, Brazil, and observed that one of 
the bottlenecks in such diagnosis is the shortage of RNA 
extraction kits and supplies, and their time-consuming 
characteristics because thousands of samples must be 
processed daily during outbreaks.
Table 3 - Analysis of the cycle threshold (Ct) values using three RNA extraction procedures in the amplification of the RNAseP 
target gene. 
Assay In house 
gene RNAseP SARS-CoV-2 (+) RNAseP SARS-CoV-2 (-)
RNA extraction procedure Loccus BioGene Quick Loccus BioGene Quick
Minimum 21 22 24 21 21 24
25% percentile 26,25 27 30 23.25 22.25 26
median 29 29 32 26 25 28.5
75% Percentile 31 32 35 28.75 28 30.75
maximum 39 38 39 36 39 36
Mean 29 29.41 31.98 26.25 26.07 28.75
Std. deviation 3.464 3.638 3.253 3,.884 4.396 3.513
Std. error 0.21 0.2206 0.1972 0.734 0.8308 0.6639
Lower 95% CI of mean 28.58 28.98 31.59 24.74 24.37 27.39
Upper 95% CI of mean 29.41 29.85 32.37 27.76 27.78 30.11
Coefficient of variation 11.94% 12.37% 10.17% 14.80% 16.86% 12.22%
Geometric mean 28.79 29.19 31.81 25.99 25.75 28.55
Lower 95% CI of geo. mean 28.38 28.76 31.42 24.58 24.22 27.25
Upper 95% CI of geo. mean 29.2 29.62 32.2 27.47 27.37 29.91
+ samples considered positive for SARS-CoV-2 in the RT-qPCR assays (n = 272, according to Materials and Methods); - samples 
considered negative for SARS-CoV-2 in the RT-qPCR assays (n = 28, according to Materials and Methods); Std. = standard; CI = 
confidence interval; geo. = geometric
Table 4 - Cost-effectiveness of the three RNA extraction procedures employed in SARS-CoV-2 molecular diagnosis using the 
Allplex 2019-nCoV assay
Parameters Loccus procedure BioGene procedure Quick procedure
Number of steps 4 4 2
Time consumption 1 h 2.5 h 30 min
Ease of performance high medium high
Number of extracted samples 32 32 32
Cost of reagents and supplies (kit) in American dollars ($) 3,429.12 7,021.80 31,020.00
Cost per extraction in American dollars ($) 107.16 28.09 93.15





High cost of buffer 
False-negative results
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Since the beginning of the pandemic, we have had 
the opportunity to use several kits for RNA extraction 
(national and from abroad), and for this study we selected 
two of Brazilian kits, which were easier to handle, being 
one automated and one manual: Loccus, kit Extracta 
Fast, and Loccus Extracta 32 equipment, SP, Brazil, and 
BioGene Extração DNA/RNA viral kit, Bioclin Quibasa, 
MG, Brazil, respectively. In May 2020, a rapid protocol 
that circumvented the need for RNA extraction, which is 
compatible with RT-qPCR-based methods, was published12; 
thus, we decided to add this protocol in the comparative 
analyses. We tested samples from a biorepository with 
two RT-qPCR kit/protocols, considering the possibility 
of discontinued supply of the Allplex kit by the Brazilian 
Ministry of Health. 
Herein, we considered the results obtained by Allplex 
kit and Loccus RNA extraction as truly positive and 
negative samples, and calculated the sensitivity, specificity, 
and Kappa index of the assays. We adopted this criteria 
considering: (i) the laboratory experience and previous 
results8, (ii) the majority of SARS-CoV-2 positive samples 
(more than 90.0%) were positive for the three target genes 
using this kit and the Loccus extraction procedure, and 
(iii) the capability of sequencing SARS-CoV-2 in several 
samples that presented discordant results among diagnostic 
assays and RNA extraction procedures. 
There was a low sensitivity of RT-qPCR assays and an 
increase in the Ct values when samples were subjected to 
the Quick RNA extraction procedure. This result can be 
explained, in part, by the presence of residues (a multitude 
of nucleic acids and proteins) in the samples or by RNA 
fragmentation during heating13. An increase of more than 
3 Ct has been described in samples tested for SARS-CoV-2 
without prior RNA extraction compared to samples that 
underwent RNA extraction by standard protocols13,14. 
The present study disclosed an overall increase of at 
least 2 Ct when the Quick procedure was employed, except 
for the RdRP gene using the Charité-Berlin protocol. 
However, only 96 samples were RdRP-positive; thus, only 
samples with high viral loads can be amplified using this 
protocol.
Another point to consider for discordant results is the 
length of the segment to be amplified (long segments are 
more prone to thermal shock degradation), and the presence 
of mutations affecting regions harboring primer-probe 
binding sites, mostly in the RdRP gene. The length of and 
the genomic segments amplified by the Allplex kit are not 
provided by the manufacturer, however, they differ from 
the segments amplified by the Charité-Berlin protocol (see 
differences in sensitivities and Ct values of E- and RdRP 
target genes using both protocols).
The literature refers to different sensitivities of assays 
for SARS-CoV-2 detection using standard RNA extraction 
protocols and protocols without RNA extraction, mostly 
when buffers are added to the samples15. In addition, low 
sensitivity of RT-qPCR assays has been associated with 
higher Ct values, i.e., samples that had Ct > 30 using 
standard RNA extraction protocols are probably going to 
be negative using quicker procedures14-16. 
Concerning the presence of mutations affecting regions 
harboring primer-probe binding sites, an in silico analysis 
of SARS-CoV-2 genomes from South America indicated 
abundant genomic diversity in the RdRP and N genes with 
respect to the E gene17. This finding highlighted a possible 
effect on the false-negative results when employing the 
RdRP target gene, and supports the results obtained here. 
To corroborate this finding, when comparing the analytical 
efficiencies and sensitivities of the primer-probe sets of 
the four most common SARS-CoV-2 qRT-PCR assays 
developed by CDC-China, CDC-USA, Charité-Berlin and 
Hong Kong University, the E gene Sarbeco (Charité) was 
the most sensitive, and the RdRP-SARS gene (Charité) was 
the least sensitive18, again corroborating the results of the 
present study. 
Future analysis of the 29 sequences that were positive 
using the Allplex kit and negative using the Charité-Berlin 
protocol could solve this issue, and confirm whether there 
are mutations in the regions harboring the primer/probes 
employed to amplify RdRP target gene corroborating 
the low sensitivity of the Charité-Berlin protocol when 
samples from Brazil were tested. A revised version of the 
PAHO/WHO laboratory guidelines recommended an 
algorithm using only the E target gene for the diagnosis of 
COVID-19 as only SARS-CoV-2 is infecting humans, and 
also due to the low sensitivity of the RdRP target gene used 
in the Charité-Berlin protocol19.
Considering the Allplex kit results as the true results, 
the Cohen’s Kappa index using RNA extracted by Loccus 
and BioGene procedures showed a perfect concordance 
(κ  =  1.000), and using the Quick procedure, an almost 
perfect concordance (κ = 0.925), allowing the quick 
protocol to be used. 
However, when analyzing the cost-effectiveness of RNA 
extraction procedures, the Quick RNA extraction, although 
having few steps and a slightly reduced time-consumption, 
it employs an expensive buffer (Lucigen) and has a lower 
sensitivity when compared to automated and manual 
procedures. The Loccus procedure, although presenting 
with the best performance, is expensive, and should be used 
when the demand for tests is very high and the result must 
be released in a short time during outbreaks and pandemics. 
The Loccus manufacturer, located in Sao Paulo, Brazil, 
Rev Inst Med Trop São Paulo. 2021;63:e52
COVID-19 laboratory diagnosis
Page 9 of 10
offers two Extracta types of equipment: Loccus Extracta 
32 and Loccus Extracta 96, allowing RNA extraction of 
32 or 96 samples in 1 h. In contrast, although the BioGene 
extraction procedure has more handling time and is more 
time-consuming, its high performance and lower cost 
(26% of the cost of the Loccus procedure) makes it a good 
choice, especially during a time of increasing health care 
expenditure and limited resources when outbreaks are 
under control. 
Several recent studies have been conducted to bypass 
RNA extraction using only hot shock procedures without 
buffer addition13-16,20-23. Thus, we are now interested in 
comparing the performance of the Quick RNA extraction 
procedure and direct approaches with no buffer in order to 
save time and expenses during pandemics.
In conclusion, although less sensitive, the Quick RNA 
extraction procedure is useful during outbreaks with the 
Allplex kit. Loccus and BioGene RNA extraction protocols 
were accurate for RT-qPCR assays, and although the 
BioGene procedure is the least expensive, the Loccus 
extraction protocol is the best choice because it allows the 
rapid handling of hundreds or thousands of samples during 
pandemics.
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